Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study

Objectives: Canakinumab is an IL-1β antibody that neutralises the activity of IL-1β. This study examined the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia. Design: This study aimed to evaluate the reduction in duration of hospitalisation with adequate oxygen...

Full description

Bibliographic Details
Main Authors: Daniele Generali, Giancarlo Bosio, Fabio Malberti, Antonio Cuzzoli, Sophie Testa, Laura Romanini, Antonio Fioravanti, Alessandro Morandini, Luca Pianta, Guglielmo Giannotti, Erika Maria Viola, Matteo Giorgi-Pierfranceschi, Marina Foramitti, Rosa Angela Tira, Ilaria Zangrandi, Giulia Chiodelli, Andrea Machiavelli, Maria Rosa Cappelletti, Alessia Giossi, Valeria De Giuli, Chiara Costanzi, Chiara Campana, Ottavia Bernocchi, Marianna Sirico, Alessia Zoncada, Alfredo Molteni, Sergio Venturini, Fabiola Giudici, Maurizio Scaltriti, Angelo Pan
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
Pneumonia
SARS-CoV-2
Canakinumab
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220325972

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220325972

Similar Items